ANTIPATHOGN

Identification and validation of novel drug targets in Gram-negative bacteria by global search: a trans-system approach

 Coordinatore UNIVERSITAT AUTONOMA DE BARCELONA 

 Organization address address: Campus UAB -BELLATERRA- s/n
city: CERDANYOLA DEL VALLES
postcode: 8193

contact info
Titolo: Ms.
Nome: Katja
Cognome: Schustakowitz
Email: send email
Telefono: 34935812940
Fax: 34935812023

 Nazionalità Coordinatore Spain [ES]
 Totale costo 7˙692˙588 €
 EC contributo 5˙943˙961 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-B
 Funding Scheme CP-FP
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-02-01   -   2013-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITAT AUTONOMA DE BARCELONA

 Organization address address: Campus UAB -BELLATERRA- s/n
city: CERDANYOLA DEL VALLES
postcode: 8193

contact info
Titolo: Ms.
Nome: Katja
Cognome: Schustakowitz
Email: send email
Telefono: 34935812940
Fax: 34935812023

ES (CERDANYOLA DEL VALLES) coordinator 966˙819.00
2    PROTEROS BIOSTRUCTURES GmbH

 Organization address address: AM KLOPFERSPITZ 19
city: MARTINSRIED
postcode: 82152

contact info
Titolo: Dr.
Nome: Dirk
Cognome: Ullmann
Email: send email
Telefono: +49 89 70076120
Fax: +49 89 70076115

DE (MARTINSRIED) participant 848˙840.00
3    FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)

 Organization address address: CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA
city: BARCELONA
postcode: 8028

contact info
Titolo: Ms.
Nome: Stella
Cognome: Serra
Email: send email
Telefono: 34934037059
Fax: 34934037059

ES (BARCELONA) participant 744˙320.00
4    DEUTSCHES KREBSFORSCHUNGSZENTRUM

 Organization address address: Im Neuenheimer Feld 280
city: HEIDELBERG
postcode: 69120

contact info
Titolo: Ms.
Nome: Bettina
Cognome: Crispin
Email: send email
Telefono: 496221000000
Fax: 496221000000

DE (HEIDELBERG) participant 698˙879.00
5    BIO-XTAL SARL

 Organization address address: ROUTE DE LA CHAPELLE 227
city: ST FELIX
postcode: 74540

contact info
Titolo: Dr.
Nome: Laurent
Cognome: Vuillard
Email: send email
Telefono: +33-4 91 82 55 70
Fax: +33-3 59 03 90 45

FR (ST FELIX) participant 541˙040.00
6    "MICROBIONTA, S.L."

 Organization address address: Ronda de Poniente - Bajo C-D 4
city: Tres Cantos
postcode: ES28760

contact info
Titolo: Dr.
Nome: Myriam
Cognome: De Grado
Email: send email
Telefono: 34915854536
Fax: 34915854506

ES (Tres Cantos) participant 533˙273.00
7    InterMed Discovery GmbH

 Organization address address: Otto-Hahn-Strasse 15
city: Dortmund
postcode: D-44227

contact info
Titolo: Dr.
Nome: Marc
Cognome: Stadler
Email: send email
Telefono: 4923200000000
Fax: 4923200000000

DE (Dortmund) participant 471˙063.60
8    RPS RESEARCH IBERICA SL

 Organization address address: VIA AUGUSTA 21-23
city: BARCELONA
postcode: 8006

contact info
Titolo: Dr.
Nome: Mas
Cognome: Jose Manuel
Email: send email
Telefono: 34932158008
Fax: 34932158016

ES (BARCELONA) participant 419˙865.72
9    FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA

 Organization address address: CARRER ROSSELLO 149-153
city: BARCELONA
postcode: 8029

contact info
Titolo: Mr.
Nome: Emili
Cognome: Bargalló
Email: send email
Telefono: 34932275707
Fax: 34934515272

ES (BARCELONA) participant 356˙720.00
10    ANAXOMICS BIOTECH, S.L.

 Organization address address: CALLE BALMES (PISO 4 - PTA 2A) 89
city: Barcelona
postcode: 8008

contact info
Titolo: Dr.
Nome: Judith
Cognome: Farrés Marisch
Email: send email
Telefono: +34 610742196
Fax: +34 932158016

ES (Barcelona) participant 231˙544.28
11    HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH

 Organization address address: Inhoffenstrasse 7
city: BRAUNSCHWEIG
postcode: 38124

contact info
Titolo: Dr.
Nome: Michael
Cognome: Straetz
Email: send email
Telefono: +49 531 6181 2020

DE (BRAUNSCHWEIG) participant 131˙596.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

gram    natural    group    clinical    structural    drugs    antipathogn    bacteria    tools    positive    interactome    bacterial    pathogenicity    discovery    resistant    negative    antimicrobial    computational    health    protein    constitute    strategy    validated    strategies    expertises    related    found    antibiotics    drug    resistance    mdr    microbiology    identification    mechanisms    compounds    biology    cell    infections   

 Obiettivo del progetto (Objective)

'Multi-drug-resistant bacterial infections are increasing at an alarming pace in both developing and developed countries and in both community and nosocomial settings. The few antimicrobial agents that have been launched during the last decade (e.g. linezolid, daptomycin) have a good activity against Gram-positive bacteria. However, multi-drug-resistant bacteria are often found among the Gram-negative group. To tackle this problem, the AntiPathoGN project proposes a novel strategy for the discovery of new antimicrobial drug targets in a number of Gram-negative bacteria. This strategy is based on a comparative, system-level analysis of molecular processes involved in pathogenicity, drug resistance, cell division and/or growth of selected pathogenic Gram-negative bacteria through a combination of computational biology, interactome discovery, in-vivo protein-blocking and structural biology techniques. This comparative analysis, at one organization level above genomics, shall permit the discovery of new potential drug targets, relevant to both species-specific and broad-spectrum antimicrobial strategies. In addition, the AntiPathoGN project will pursue the identification of novel antibacterial compounds acting against previously validated targets by screening purpose-specific libraries of products derived from natural resources and from synthetic compounds. An important aspect of the project is that more than one approach is planned for the key objectives of target identification, target validation, target characterisation, and hit finding. The AntiPathoGN consortium is composed of 1 university bringing expertises in computational biology and microbiology, 3 research centres with expertises in computational and experimental interactomics, structural biology and clinical microbiology, and 7 SMEs with records on recombinant-antibody technology, structural biology, drug discovery and clinical research. The AntiPathoGN project fully addresses topic HEALTH-2007-2.3.1-1.'

Introduzione (Teaser)

Multidrug-resistant (MDR) bacteria constitute one of the major threats to public health worldwide. The lack of new antimicrobial drugs available on the market is fuelling the spread of MDR infections.

Descrizione progetto (Article)

The shortage of antibiotics for MDR infections caused by gram-negative bacteria is particularly critical. Bacteria from this group are the main cause of death among patients with hospital-acquired infections. The cell structure of gram-negative bacteria makes them more difficult to attack with drugs than gram-positive organisms.

Existing antibiotics target mechanisms or structures that are essential for bacterial survival or growth. This offers a rapid solution, but leads to possibility of MDR bacteria selection. Alternative strategies target mechanisms related to development of infection.

The EUfinanced the http://www.antipathogn.eu (ANTIPATHOGN) project to discover new targets and treatments that are less prone to development of drug resistance. ANTIPATHOGN studied mechanisms related to pathogenicity of Gram-negative bacteria to find new drug targets, or combinations of targets, and active compounds against them. The researchers focused on high-priority MDR bacteria such as Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii, Helicobacter pylori and Stenotrophomonas maltophilia.

A major achievement of ANTIPATHOGN was the generation of a database of protein interaction (interactome) networks available for gram-negative bacteria. The consortium has identified phenotypically and validated 18 potential antimicrobial targets in gram-negative bacteriaand found potential drugs against two of them. Two of the targets are essential for bacterial growth, while the other sixteen are involved in various mechanisms related to virulence or resistance.

Cell-based screens have identified 33 natural products with antimicrobial activity, including 3 novel compounds. Further studies will confirm the potential of these targets and compounds for antimicrobial drug development.

The results of the project have been presented at 19 scientific conferences and have produced 54 publications in top-ranking journals. Information about new developments of ANTIPATHOGN is available through its website.

The databases and tools generated by ANTIPATHOGN constitute a fundamental contribution to the knowledge platform on MDR bacteria. The consortium has provided new data on the biology of gram-negative bacteria and transformed them into tools that can be used for the development of new drugs for MDR bacteria.

Altri progetti dello stesso programma (FP7-HEALTH)

ATPBONE (2008)

Fighting osteoporosis by blocking nucleotides: purinergic signalling in bone formation and homeostasis

Read More  

SYSTEMS MICROSCOPY (2011)

Systems microscopy – a key enabling methodology for next-generation systems biology

Read More  

PERSIST (2009)

Persisting Transgenesis

Read More